39results about How to "Broad-spectrum antiviral activity" patented technology

The invention discloses application of GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2, 2)-biphenylethyl)amino]propoxy)phenylacetate hydrochloride) in preparation of drugs treating or preventing hepatitis C virus. A drug without any toxic concentration is chosen for an antiviral experiment, the influence of GW3965 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the GW3965 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. The anti-virus capability of drug combination of GW3965 and other anti-HCV drugs is detected, and results show that the compound has the potential of drug combination with other drugs. GW3965 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target clinically. And drug combination can achieve a good effect.

The invention belongs to the technical field of medicine and relates to the application of carbinoxamine maleate in the preparation of anti-influenza A virus medicine. Experiments have shown that the carbinoxamine maleate has significant anti-influenza activity to different types and subtypes of influenza viruses at a completely non-toxic concentration, and inhibits the replication of all detected virus strains in a dose-dependent manner, indicating that Carbinoxamine maleate has a certain broad-spectrum anti-influenza virus activity, and the influenza virus described in the present invention includes influenza A and influenza B viruses, including H1N1, H3N2, H7N9, H5N1, H7N1, H7N2, H7N3, H7N7, H9N2 Or type B; the mechanism of action research of the present invention shows that carbinoxamine maleate mainly inhibits the virus from entering host cells by interfering with the endocytosis of influenza virus; described carbinoxamine maleate can be prepared for the prevention and treatment of influenza medicine , to provide new ways and means for the prevention and treatment of influenza.

The invention discloses an application of enilconazole in preparing a drug for treating or preventing influenza virus infections. Firstly, toxicity of enilconazole to MDCK cells is detected. The result shows that the maximum non-toxic concentration of enilconazole is 100.0 [mu]M. Secondly, antiviral activity of enilconazole is measured within a completely non-toxic concentration range. The result shows that the small molecular compound has significant antiviral activity and the antiviral activity presents a dosage-dependent effect. Finally, the antiviral activities of enilconazole to influenza viruses in different types and subtypes are detected. The results show that enilconazole can suppress replication of all the detected influenza virus strains in a dose-dependent manner, so that the anti-influenza virus activity of enilconazole has a broad spectrum. Therefore, enilconazole disclosed by the invention is a novel broad-spectrum anti-influenza virus drug and can be used for preparing the drug for treating or preventing the influenza virus infections.

The invention discloses application of chlorpheniramine maleate in preparation of medicaments for treating or preventing influenza virus. The application comprises the following steps of: first, performing an antivirus experiment by selecting the chlorpheniramine maleate with completely non-toxic concentration, wherein the result shows that the low molecular weight compound has remarkable antiviral activity and has dose-dependent correlation; then, analyzing the anti-influenza virus action cycle of chlorpheniramine maleate, wherein the result shows that chlorpheniramine maleate mainly inhibits the early virus infection events of virus adsorption, entry and the like; and finally, detecting the antiviral activity of chlorpheniramine maleate on different types or subtypes of influenza virus, wherein the result shows that chlorpheniramine maleate can inhibit the replication of all detection virus strains and has a dose-dependent effect, and shows that the anti-influenza virus activity of chlorpheniramine maleate has certain broad spectrum. Therefore, chlorpheniramine maleate disclosed by the invention can be developed as a new anti-influenza virus medicament, and provides a new way and a new means for treating the influenza virus.